DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR TANDUTINIB
» See Plans and Pricing
Clinical Trials for Tandutinib
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00297921 | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy | Withdrawn | Millennium Pharmaceuticals, Inc. | Phase 1/Phase 2 | Prospective, nonrandomized, noncomparative, open-label, multicenter, 2-stage clinical study designed to determine the overall response (combined complete remission, complete remission with incomplete blood count recovery, partial remission, or blast response) rate following tandutinib therapy in 2 groups of patients with newly diagnosed Acute Myelogenous Luekemia. |
| NCT00379080 | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | Completed | National Cancer Institute (NCI) | Phase 1/Phase 2 | This phase I/II trial is studying the side effects and best dose of tandutinib and to see how well it works in treating patients with recurrent or progressive glioblastoma.Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. |
| NCT00390468 | Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases | Completed | National Cancer Institute (NCI) | Phase 2 | RATIONALE: Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well tandutinib works in treating patients with progressive prostate cancer and bone metastases. |
| NCT00408902 | Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | This phase II trial is studying how well tandutinib works in treating patients who have undergone surgery for metastatic kidney cancer. Tandutinib may stop the growth of kidney cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving tandutinib after surgery may kill any tumor cells that remain after surgery. |
| NCT00667394 | Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | Completed | National Cancer Institute (NCI) | Phase 2 | Background: In order to survive, brain tumors must have a network of blood vessels to supply it with oxygen and nutrients. The tumors produce substances that enable new blood vessels to form. Tandutinib and Bevacizumab are experimental drugs that may prevent new blood vessel formation and thereby slow or stop tumor growth in the brain. Objectives: To determine the safety and side effects of Tandutinib in combination with Bevacizumab in patients with brain tumors. To evaluate the response of brain tumors to treatment with Tandutinib and Bevacizumab. Eligibility: Patients 18 years of age and older with a malignant brain tumor for whom standard treatments (surgery, radiation and chemotherapy) are no longer effective. Design: Patients receive treatment in 4-week cycles as follows: Tandutinib by mouth twice a day every day and intravenous (through a vein) infusions of Bevacizumab over 90 minutes (or less if well tolerated) every 2 weeks. Treatment may continue for up to 1 year, and possibly longer, as long as there are no signs of tumor growth or serious treatment side effects. Patients are evaluated with magnetic resonance imaging (MRI), computed tomography (CT) and positron emission tomography (PET) scans before starting treatment and then periodically to determine the response to treatment. Patients have physical and neurological examinations every 4 weeks and blood tests every 2 weeks. They complete quality of life questionnaires every 4 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Tandutinib
Condition Name
Clinical Trial Locations for Tandutinib
Trials by Country
Clinical Trial Progress for Tandutinib
Clinical Trial Phase
Clinical Trial Sponsors for Tandutinib
Sponsor Name
